Evaluation and intervention of chronic heart failure complicated with asthenia in elderly

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400087122

Enrollment

Unknown

Registered

2024-07-19

Start date

2024-07-20

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure complicated with asthenia in elderly

Interventions

only HF group:Heart failure medication

HFEF with frailty group:Intervention of exercise, nutrition, correction of inappropriate drug use, psychological and residential environment

Eligibility

Sex/Gender

All

Age

60 Years to 100 Years

Inclusion criteria

Inclusion criteria: Screening of elderly patients with chronic heart failure during the geriatric study enrollment period; Definitions: Patients aged = 60 years are defined as elderly patients. According to the Chinese expert consensus (2021) for the diagnosis and treatment of chronic heart failure in the elderly, N-terminal B-type natriuretic peptide pro (NT-proBNP) is used for the screening and diagnosis of heart failure, and > 220 ng/L can diagnose chronic heart failureNT-proBNP > 660 ng/L with atrial fibrillation rhythm can be diagnosed as patients with chronic heart failure.

Exclusion criteria

Exclusion criteria: 1. Unable to cooperate with the assessment process and refuse to sign the informed consent form; 2. Those who fail to effectively control local or systemic bacterial infection in the acute stage; 3. Patients with shock (blood pressure lower than 90/60mmHg) and critically ill patients, who are at risk of changing their condition at any time, and cannot cooperate with the operation and evaluate the effect; 4. Those with mental and neurological diseases who cannot cooperate with doctors; 5. Patients with malignant tumors and diseases that affect life expectancy

Design outcomes

Primary

Measure	Time frame
General assessment (Modified Barthel Index Rating Scale PADL);Assessment of somatic functional status;Balance and Gait;Nutritional assessment;Psychopathological assessment;Pain assessment;Co-morbidity assessment;Multiple medication assessment;Sleep Quality Assessment;Social support assessment;Home Environment Assessment (HEA);TNF-a;CX3CL1;FT3;routine blood test;serum transferrin;Total protein, albumin, fibrinogen;Dual-energy X-ray;	—

Measure

Time frame

General assessment (Modified Barthel Index Rating Scale PADL);Assessment of somatic functional status;Balance and Gait;Nutritional assessment;Psychopathological assessment;Pain assessment;Co-morbidity assessment;Multiple medication assessment;Sleep Quality Assessment;Social support assessment;Home Environment Assessment (HEA);TNF-a;CX3CL1;FT3;routine blood test;serum transferrin;Total protein, albumin, fibrinogen;Dual-energy X-ray;

—

Secondary

Measure	Time frame
Heart failure readmission rate;infection rate;Acute cardiovascular event rate;disability rate;all-cause mortality;Sum of heart failure readmission rate, infection rate, acute cardiovascular event rate, disability rate and all-cause mortality rate;	—

Countries

China

Contacts

Public ContactHUANG LIHONG

China-Japan Union Hospital of Jilin University

lhhuang@jlu.edu.cn+86 189 0431 7555

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026